Scale -


  • Revenue is 28163 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Ebitda is 6765 Rs Cr; in Top Quartile; Annual Decline is -15 %
  • PBT is 1082 Rs Cr; in Top Quartile; 5 Year CAGR is 11 %; Annual Decline is -23 %
  • PAT is 3870 Rs Cr; in Top Quartile; 5 Year CAGR is 11 %; Annual Decline is -27 %
  • Quarterly Revenue is 7077 Rs Cr; in Top Quartile

Profitability -


  • PBDIT Margin is 24.02 %; Annual Decline is -17 %
  • PAT Margin is 13.74 %; Annual Decline is -28 %
  • Quarterly Ebitda Margin is 17 %; in Bottom Quartile
  • Quarterly Profit margin is 11 %; in Bottom Quartile

Return -


  • ROCE is 15.65 %; Annual Decline is -27 %; Continuous Decline over 3 years
  • ROA is 9.12 %; Annual Decline is -35 %
  • ROE is 11.26 %; Annual Decline is -33 %; in Bottom Quartile
  • Asset Turnover is 71 %; Continuous Decline over 3 years

Efficiency -


  • Current Ratio is 3.44; in Top Quartile
  • Quick Ratio is 2.5; in Top Quartile
  • Operating cash flow is 3940 Rs Cr; in Top Quartile
  • Inventory Turnover Ratio is 4.6; 5 Year CAGR is 60 %

Solvancy -


  • Contingent Liabilities is 3546 Rs Cr; Continuous Decline over 3 years; in Top Quartile; 5 Year CAGR is 29 %
  • Debt/Equity is 0.01; 5 Year CAGR is -29 %
  • Long term Debt is 117 Rs Cr; 5 Year CAGR is -27 %; Annual Growth is 881 %; Continuous Growth over 3 years
  • Total Debt is 258 Rs Cr; 5 Year CAGR is -25 %; Annual Growth is 180 %

Quality -


  • Change in Inventories/Total Expenses is -3 %; Annual Decline is -105 %; Continuous Decline over 3 years
  • Other Expenses/Total Expenses is 28 %; Continuous Growth over 3 years
  • Current Tax/PAT is 37 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem


Sector
Major Subsidiaries/Associates
Key Clients

Products


Products
Product details

Operations


Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
Cipla Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Cipla Appoints Former Castrol India CFO Rashmi Joshi as Independent Director for Five Years
Cipla appoints Rashmi Joshi as additional independent director
Cipla Ltd (BOM:500087) (Q2 2027) Earnings Call Highlights: Strong India Growth and US Ramp-Up ...
Cipla Q2 Results Review: ICICI Securities Remains Bullish After Inline Numbers; Check Target Price
Stock Picks Today: Maruti Suzuki, Bajaj Auto, L&T, Paytm, SBI Life, And More On Brokerages' Radar
Cipla Eyes Margin Rebound From FY28 As Middle East Freight Squeeze Hits Q2 Costs
Cipla Q2 results: Net profit plunges 35% to Rs 878 crore, revenue down 2.4% YoY; stock falls
Cipla Q2 Results: Profit falls 35%, Misses Estimates; Margin Contracts
Cipla Q2 Results: US sales meet expectations, margins narrow from last year
Cipla Q2FY27 slides: India revenue surges amid margin pressure By Investing.com
Cipla slips after Q2 PAT drops 35% YoY
CIPLA: Q2 growth and margin improved as management maintained ambitious U.S. launch-led guidance
CIPLA: Q2 revenue and profit fell YoY; NPPA litigation remains a significant exposure
CIPLA: Record One India revenue offset by lower consolidated EBITDA and PAT
Earnings call transcript: Cipla Q2 2027 revenue rises as stock slips 1.85%
Indian drugmaker Cipla misses profit view on US weakness, shares slip
Q2 results: L&T, Bajaj Auto, Maruti Suzuki, Cipla among 110 firms on Oct 27
Cipla Q2 Preview: Net Profit Seen Falling 29% As US Business Faces Headwinds
Gaurav Kaul Takes Charge as Managing Director & CEO of Cipla Health Ltd
Cipla reports record Q1FY27 revenue of ?7,119 crore
Cipla Ltd Estimates – NSE:CIPLA
Weekly Recap: Cipla Ltd below 200-week EMA and MF holdings up 2.6%
Gaurav Kaul appointed MD & CEO of Cipla Health
Maharashtra FDA cancels Cipla Pharma’s Pune drug sale licences after Bombay HC directed fresh hearing
FDA cancels Cipla’s wholesale drug licence at Pune warehouse | Hindustan Times
Reactin Plus Violations: Maharashtra FDA Cancels Cipla Warehouse Licences
Cipla on Maharashtra FDA action: ‘Disappointing’, says Pune warehouse follows protocols
Cipla's Pune Godown Loses Drug Licence Over 'Misbranding, Storage Violations'
FDA cancels wholesale drug sales license of Cipla Pharma & Life sciences Ltd
Maharashtra FDA Cancels Drug Sale Licence Of Pune Cipla Facility; Disappointing Decision, Says Firm
Tukaram Mundhe in action! Maharashtra FDA cancels Cipla's Pune drug sale licence